Skip to Main Content

Paper Details

Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.
Sci Adv
81
2019
CD8, CD8+, CD8+ T cell populations, DDR2, PD-1, anti-, anti-PD-, anti-PD-1, bladder, cancer, dasatinib, melanoma, mice, patients, sarcoma, tumor, tumors, tyrosine, tyrosine kinase
Author NameAffiliation
Andrii I RozhokUniversity of Colorado School of Medicine
Neeraj AgarwalUniversity of Colorado Anschutz Medical Campus
James C CostelloUniversity of Colorado Anschutz Medical Campus
  • 1 - 3

Datasets

Release 1.2